Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test.Please watch the video at Investors.com - The Cell Therapy Market Is ...
Surgical intervention remains a cornerstone of colorectal cancer treatment. In recent years, robotic surgery has emerged as a promising approach, offering potential advantages over traditional open ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the first set of abstracts have been released from several studies that will be shared at the ...